Na+, K+ ATPase activity is markedly reduced by cis-4-decenoic acid in synaptic plasma membranes from cerebral cortex of rats.
We have previously demonstrated that octanoic (OA) and decanoic acids (DA) inhibit Na+, K+ ATPase activity in synaptic plasma membranes from rat brain. The objective of the present study was to investigate the in vitro effects of the other metabolites that accumulate in tissues of medium-chain acyl-CoA dehydrogenase (MCAD)-deficient patients, namely cis-4-decenoic acid (cDA), octanoylcarnitine (OC), hexanoylcarnitine (HC), hexanoylglycine (HG), phenylpropionylglycine (PPG) and suberoylglycine (SG), on Na+, K+ ATPase activity in synaptic plasma membrane from cerebral cortex of 30-day-old rats. cDA, the pathognomonic compound found in this disorder, provoked the strongest inhibition on this enzyme activity at concentrations as low as 0.25 mM, whereas OC inhibited this activity at 1.0 mM and higher concentrations in a dose-dependent manner. In contrast, HC, HG, PPG and SG did not affect Na+, K+ ATPase activity. Furthermore, pre-treatment of cortical homogenates with the antioxidant enzymes catalase plus superoxide dismutase totally prevented cDA-induced Na+, K+ ATPase inhibition. We also provided evidence that cDA, as well as OA and DA, caused lipid peroxidation, which may explain, at least in part, the inhibitory properties of these compounds towards Na+, K+ ATPase. Considering that Na+, K+ ATPase is a critical enzyme for normal brain development and functioning, it is presumed that these findings, especially those regarding to the marked inhibitory effect of cDA, may be involved in the pathophysiology of the neurological dysfunction of MCAD-deficient patients.
de Assis
D R
DR
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, Brazil.
Maria
R C
RC
Ferreira
G C
GC
Schuck
P F
PF
Latini
A
A
Dutra-Filho
C S
CS
Wannmacher
C M D
CM
Wyse
A T S
AT
Wajner
M
M
D042964:Acyl-CoA Dehydrogenase / Q000172:deficiency; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002331:Carnitine / Q000031:analogs & derivatives / Q000494:pharmacology; D002540:Cerebral Cortex / Q000187:drug effects / Q000201:enzymology*; D004791:Enzyme Inhibitors; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects; D008163:Luminescent Measurements; D051381:Rats; D017208:Rats, Wistar; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors*; D013570:Synaptic Membranes / Q000187:drug effects / Q000201:enzymology*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
D000975:Antioxidants; D004791:Enzyme Inhibitors; D005229:Fatty Acids, Monounsaturated; D017392:Thiobarbituric Acid Reactive Substances; C055444:4-decenoic acid; D042964:Acyl-CoA Dehydrogenase; D000254:Sodium-Potassium-Exchanging ATPase; C008698:octanoylcarnitine; D002331:Carnitine